In our subgroup analysis of specific disease subtypes and treatment statuses, we observed that patients with CLL and WM/LPL, as well as both treatment-naïve and relapsed/refractory patients, who discontinued BTKi due to toxicity or within 6 months had significantly shorter post-BTKi survival (Supplementary Figure 3). This evidence concerns the gene LPL and B-cell chronic lymphocytic leukemia.